<DOC>
	<DOCNO>NCT00909831</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , hydroxychloroquine , work different way stop growth tumor cell , either kill cell stop dividing . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Giving hydroxychloroquine together temsirolimus may kill tumor cell . PURPOSE : This phase I trial study side effect best dose hydroxychloroquine give together temsirolimus treat patient metastatic solid tumor respond treatment .</brief_summary>
	<brief_title>Hydroxychloroquine Temsirolimus Treating Patients With Metastatic Solid Tumors That Have Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose hydroxychloroquine ( HCQ ) combination temsirolimus ( TEM ) patient metastatic refractory solid tumor . Secondary - Describe toxicity regimen patient . - Measure response rate patient treat regimen . Tertiary - Establish population pharmacokinetic ( PK ) model HCQ metabolites combination TEM . - Use population PK model estimate exposure HCQ individual patient . - Compare PK parameter regimen data publish single agent study . - Measure change median number autophagic vesicles/cell peripheral blood mononuclear cell TEM alone TEM HCQ correlate change HCQ exposure . OUTLINE : This dose-escalation study hydroxychloroquine . Patients receive temsirolimus IV 30 minute week begin week 1 oral hydroxychloroquine twice daily begin week 2 . Courses repeat every 8 week absence disease progression unacceptable toxicity . Blood sample collect baseline periodically study pharmacokinetic pharmacodynamic study measurement autophagy inhibition . Samples analyze via HPLC tandem mass spectrometry , immunoblotting assay , electron microscopy .</detailed_description>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory solid tumor curative standard therapy exist Metastatic disease Treated brain metastasis stable ≥ 3 month allow At least 1 week since prior steroid PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2 time upper limit normal ( ULN ) ALT AST ≤ 5 time ULN Total bilirubin ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent infection medical illness would jeopardize ability patient receive treatment outline protocol reasonable safety No prior concurrent malignancy except curatively treat carcinomainsitu site basal cell carcinoma squamous cell carcinoma skin Patients free disease ( prior malignancy ) ≥ 5 year eligible No porphyria No psoriasis , except well control psoriasis care specialist No previously document macular degeneration diabetic retinopathy No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics Any number type prior anticancer therapy allow No prior mTOR inhibitor At least 4 week since prior immunotherapy ( i.e. , aldesleukin , interferon , CTLA4 ) chemotherapy recover At least 2 week since prior oral target therapy recover At least 4 week since prior concurrent investigational anticancer therapy ( except vaccine ) No concurrent therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent cytochrome P450 enzymeinducing anticonvulsant drug ( i.e. , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) Concurrent nonenzyme induce anticonvulsant , include felbamate , valproic acid , gabapentin , lamotrigine , tiagabine , topiramate , zonisamide , levetiracetam allow Concurrent hematologic growth factor ( filgrastim [ GCSF ] , pegfilgrastim , epoetin alfa ) allow patient severe myelosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>